CENTRAL EEG ANALYSIS & ADVICE FOR CLINICAL TRIALS
EEG is the most direct measure of neuronal and synaptic function, with millisecond precision. For (mono/multicenter) clinical trials, we can take care of all EEG-related processes: site instruction & coaching, cloud data storage, and a wide array of modern analysis techniques.
During the startup phase, we provide advice on study design, coach sites to provide high quality EEG data, and help to set up the EEG trial infrastructure. In running studies, we provide fast quality checks and feedback to sites to optimize data. In the end phase, we provide an extensive quantitative analysis report of the blinded data. After the (unblinded) statistical analysis, we interprete EEG outcomes and present/ publish results.
With EEGlab trial data, we are also in the position to closely study longitudinal changes in treated and placebo groups (useful for sample size calculation), and to test novel effect monitoring markers.
RELATED PUBLICATIONS
DRUG DEVELOPMENT
In this book on drug development in Alzheimer's disease, we provide the chapter on involving EEG in trial design.
EEG STABILIZATION IN A CLINICAL TRIAL
Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
PROGNOSTIC EEG MARKER ACCURACY
EEG spectral analysis as a putative early prognostic biomarker in nondemented, amyloid positive subjects. In amyloid positive subjects with normal cognition, slowing of oscillatory brain activity is related to clinical progression.
TREATMENT EFFECTS ON AD CONNECTIVITY
The functional connectivity measure corrected Amplitude Envelope Correlation (AEC-c) may be a sensitive marker to detect treatment effects in AD